培非格司亭用于小细胞肺癌患者二线氨柔比星治疗时发热性中性粒细胞减少的一级预防。
Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy.
机构信息
Department of Pharmacy, Gifu University Hospital, Gifu, Japan.
Laboratory of Pharmacy Practice and Social Science, Gifu Pharmaceutical University, Gifu, Japan.
出版信息
Anticancer Res. 2021 Mar;41(3):1615-1620. doi: 10.21873/anticanres.14923.
BACKGROUND/AIM: We evaluated the efficacy of primary prophylaxis with pegfilgrastim (PEG) for febrile neutropenia (FN) in small cell lung cancer (SCLC) patients receiving amrubicin (AMR).
PATIENTS AND METHODS
A retrospective cohort study was conducted in patients with SCLC receiving AMR as second-line therapy.
RESULTS
A total of 33 patients were treated with AMR (no PEG group), while 13 patients were treated with AMR plus prophylactic administration of PEG (PEG group). The severity of neutropenia was significantly reduced in the PEG group compared to the no PEG group (p=0.02). The incidence of FN in the no PEG and PEG groups was 27.3% and 7.7%, respectively. The time to development of FN tended to be longer in the PEG group compared to the no PEG group (p=0.132).
CONCLUSION
Primary prophylaxis with PEG may be beneficial in reducing the risk of FN in patients with SCLC receiving AMR.
背景/目的：我们评估了培非格司亭（PEG）在接受氨柔比星（AMR）治疗的小细胞肺癌（SCLC）患者中进行发热性中性粒细胞减少（FN）一级预防的疗效。
患者和方法
对接受 AMR 二线治疗的 SCLC 患者进行了回顾性队列研究。
结果
共 33 例患者接受 AMR 治疗（无 PEG 组），13 例患者接受 AMR 联合 PEG 预防性治疗（PEG 组）。PEG 组的中性粒细胞减少严重程度明显低于无 PEG 组（p=0.02）。无 PEG 组和 PEG 组 FN 的发生率分别为 27.3%和 7.7%。PEG 组 FN 的发生时间较无 PEG 组有延长的趋势（p=0.132）。
结论
在接受 AMR 治疗的 SCLC 患者中，PEG 的一级预防可能有助于降低 FN 的风险。
Zotero 插件